Division of Valeant Pharmaceuticals International/Tecnofarma SA
Latest From Tecnofarma SA
Biopharmaceutical company financings more than doubled to $2.7 billion from Q3. There were 23 acquisitions bringing in a total of $17.7 billion. And in alliances there was a focus on biosimilars, oncology and neurology deals, and unique partnerships with clear paths to exits.
- Generic Drugs
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Valeant Pharmaceuticals International
- Senior Management
- Contact Info
Phone: (52) 55 5654 3000
Saffron 123, Col. Granjas México
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.